Sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-03-03
DOI
10.1111/dom.14684
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: a Descriptive Analysis in the UK CPRD
- (2021) Ruth E. Farmer et al. CLINICAL THERAPEUTICS
- Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin
- (2021) Ricardo Fontes-Carvalho et al. European Journal of Preventive Cardiology
- Evaluation of clinical and antidiabetic treatment characteristics of different sub-groups of patients with type 2 diabetes: Data from a Mediterranean population database
- (2021) Manel Mata-Cases et al. Primary Care Diabetes
- Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation
- (2021) Hiddo J. L. Heerspink et al. Clinical Journal of the American Society of Nephrology
- Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
- (2021) Su Jin Jeong et al. BMC Nephrology
- Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US
- (2021) Lauren A. Eberly et al. JAMA Network Open
- Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
- (2021) Kamlesh Khunti et al. Cardiovascular Diabetology
- Are All SGLT2 Inhibitors Created Equal?
- (2021) L. Parker Gregg et al. Clinical Journal of the American Society of Nephrology
- Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease, a Cohort Study
- (2021) Samantha T. Harris et al. DIABETES CARE
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2021) Theresa A McDonagh et al. EUROPEAN HEART JOURNAL
- Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease
- (2021) Glenn M. Chertow et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013–2018
- (2020) Chintan V. Dave et al. DIABETES CARE
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2020 EXECUTIVE SUMMARY
- (2020) Alan J. Garber et al. Endocrine Practice
- Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
- (2020) André J Scheen Expert Opinion On Drug Safety
- Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon‐Like Peptide‐1 Receptor Agonist and Sodium‐Glucose Cotransporter‐2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta‐Analysis
- (2020) Mengdie Hu et al. Journal of the American Heart Association
- Assessing the cost‐effectiveness of SGLT2i in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real‐world evidence
- (2020) Phil McEwan et al. DIABETES OBESITY & METABOLISM
- 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
- (2020) Sandeep R. Das et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- TEMPORARY REMOVAL: Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: Evidence-based advances in monitoring and treatment
- (2020) Ian H. de Boer et al. KIDNEY INTERNATIONAL
- A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe
- (2020) S. Seidu et al. Primary Care Diabetes
- Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
- (2020) Guntram Schernthaner et al. Cardiovascular Diabetology
- Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
- (2020) André J. Scheen Nature Reviews Endocrinology
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- (2020) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025
- (2020) Xiling Lin et al. Scientific Reports
- GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
- (2020) Michael A. Nauck et al. Molecular Metabolism
- Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program
- (2020) Jing Luo et al. JAMA Network Open
- Trends in diabetes medication use in Canada, England, Scotland and Australia: a repeated cross-sectional analysis (2012-2017)
- (2020) Michelle Greiver et al. BRITISH JOURNAL OF GENERAL PRACTICE
- Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk
- (2020) Francesco Giorgino et al. Cardiovascular Diabetology
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- Global survey investigating causes of treatment inertia in type 2 diabetes cardiorenal risk management
- (2020) Naresh Kanumilli et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial
- (2020) Bettina J. Kraus et al. KIDNEY INTERNATIONAL
- Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists
- (2019) Orly Vardeny et al. JACC-Heart Failure
- Think-aloud study about the diagnosis of chronic heart failure in Belgian general practice
- (2019) Miek Smeets et al. BMJ Open
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2019 EXECUTIVE SUMMARY
- (2019) Alan J. Garber et al. Endocrine Practice
- Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
- (2019) Maria J. Pereira et al. DRUGS
- Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
- (2019) David R. Matthews et al. DIABETOLOGIA
- Time trends in prescribing of type 2 diabetes drugs, glycemic response and risk factors: a retrospective analysis of primary care data, 2010‐2017
- (2019) John M Dennis et al. DIABETES OBESITY & METABOLISM
- Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
- (2019) Eri T. Kato et al. CIRCULATION
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus
- (2019) Jung-Im Shin Current Diabetes Reports
- 1224-P: Improving Compliance with SGLT2 Inhibitors by Reducing the Risk of Genital Mycotic Infections: The Outcomes of Personal Hygiene Advice
- (2019) SCOTT M. WILLIAMS et al. DIABETES
- WITHDRAWN: Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition
- (2019) Pouya Saeedi et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases
- (2019) Alaaeldin Bashier et al. Diabetology & Metabolic Syndrome
- Treatment Patterns of Diabetes in Italy: A Population-Based Study
- (2019) Aida Moreno Juste et al. Frontiers in Pharmacology
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort Study
- (2019) Rozalina G. McCoy et al. Diabetes Technology & Therapeutics
- Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis
- (2019) Martin B. Whyte et al. PLOS MEDICINE
- Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
- (2019) Bryce C Simes et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETES CARE
- A Multinational Real-World Study on the Clinical Characteristics of Patients with Type 2 Diabetes Initiating Dapagliflozin in Southern Europe
- (2019) Gian Paolo Fadini et al. Diabetes Therapy
- Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017
- (2018) Thomas R. Einarson et al. Cardiovascular Diabetology
- Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
- (2018) Beatrice C. Lupsa et al. DIABETOLOGIA
- Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines
- (2018) Kristina Klara et al. JOURNAL OF GENERAL INTERNAL MEDICINE
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project
- (2017) Suzanne V Arnold et al. European Journal of Preventive Cardiology
- Barriers to effective management of type 2 diabetes in primary care: qualitative systematic review
- (2016) Bruno Rushforth et al. BRITISH JOURNAL OF GENERAL PRACTICE
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences
- (2015) Linda A Gallo et al. Diabetes & Vascular Disease Research
- Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
- (2015) Ngozi Erondu et al. DIABETES CARE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanism linking diabetes mellitus and obesity
- (2014) Abdullah Algoblan et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Clinical inertia in management of T2DM
- (2010) Azhar Zafar et al. Primary Care Diabetes
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started